Perspectives of molecular imaging and radioimmunotherapy in lymphoma.
Radiol Clin North Am
; 46(2): 243-52, viii, 2008 Mar.
Article
en En
| MEDLINE
| ID: mdl-18619379
ABSTRACT
Successful treatment of Hodgkin lymphomas and non-Hodgkin lymphomas depends on accurate staging and prognostic estimations, as well as evaluation of response to therapy as early after initiation as possible. We focus on several aspects of molecular imaging and therapy that affect the management of patients who have lymphoma. First, we review prior use of gallium-67 citrate for evaluation of lymphoma patients, mainly from a historical perspective, since it was the mainstream lymphoma functional imaging tracer for decades. Next, we review current clinical uses of 18F Fluoro-2-Deoxyglucose (18F FDG) PET and PET/CT for evaluation of lymphoma patients and use of radioimmunotherapy in lymphoma. Finally, we discuss advances in molecular imaging that may herald the next generation of PET radiotracers after 18F FDG.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Radioinmunoterapia
/
Tomografía de Emisión de Positrones
/
Linfoma
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Radiol Clin North Am
Año:
2008
Tipo del documento:
Article
País de afiliación:
Estados Unidos